Effects of targeted-edited oncogenic insulin-like growth factor-1 receptor with specific-sgRNA on biological behaviors of HepG2 cells

Figure 1 Expression of insulin-like growth factor-1 receptor or P-glyco protein with cumulative survival of hepatocellular carcinoma patients. Liver insulin-like growth factor-1 receptor (IGF-1R) or P-glyco protein (P-gp) in the hepatocellular carcinoma (HCC) group were analyzed using immunohistochemistry (IHC) with anti-human IGF-1R or P-gp antibodies. A: The IGF-1R staining in HCC by IHC (× 200); B: The IGF-1R staining in distal non-cancerous tissues (non-Ca, × 200); C: The specific concentration of IGF-1R/per mg wet liver in the HCC (78.62 ± 18.42 pg) or non-Ca (31.22 ± 6.38 pg) group; D: The IGF-1R by Western blotting (130 kDa, upper) and the ratios form IGF-1R to β-actin (down). Similar to hepatic IGF-1R, E: The P-gp staining in HCC by IHC (× 200); F: The P-gp staining in non-Ca (× 200); G: The specific concentration of P-gp/per mg wet liver in the HCC (8.52 ± 3.49 ng) or D-can (1.28 ± 0.46 ng) group; H: The P-gp by Western blotting (142 kDa, upper) and the ratios form IGF-1R to β-actin (down). I: The cumulative survival curve of HCC patients with high IGF1R expression. J: The cumulative survival curve of HCC patients with high P-gp expression.